Research progress on treatment-associated pneumonitis in lung cancer patients undergoing radiotherapy and immunotherapy

Radiotherapy and immunotherapy - both important facets of modern cancer treatment - provide therapeutic benefits, but also raise concerns from potential concomitant adverse effects. One such adverse event, treatment-associated pneumonitis (TAP), can cause profound changes in quality of life of patients with thoracic malignancies. The aim of this review is to elucidate the pathogenesis, incidence, risk factors, differential diagnosis, and management of pneumonitis induced by the combination of radiotherapy and immunotherapy for lung cancer.